Last updated on May 2019

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease


Brief description of study

The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for end points for the studies E2609-G000-301 (NCT02956486) and E2609-G000-302 (NCT03036280) will be pooled.

Clinical Study Identifier: NCT02956486

Find a site near you

Start Over

Eisai Trial Site 1

Suminoe-ku, Japan
2.52miles
  Connect »

Eisai Trial Site 1

Naniwa-Ku, Japan
6.03miles
  Connect »

Eisai Trial Site 1

Osaka-shi, Japan
8.4miles
  Connect »

Eisai Trial Site 2

Osaka-shi, Japan
8.4miles
  Connect »

Eisai Trial Site 3

Osaka-shi, Japan
8.4miles
  Connect »

Eisai Trial Site 1

Osaka, Japan
8.4miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.